Evidence map›Paper›PMID 36368737›Full record

ArticleBMJ case reports2022

Siponimod-related bilateral cystoid macular oedema and intravenous fluorescein angiographic findings in a patient with stable proliferative diabetic retinopathy without history of diabetic macular oedema.

William F Foos, Catherine Culp, Masumi Asahi, Marena Patronas

Open access · hybridAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Siponimod-associated cystoid macular edema without known risk factors.American journal of ophthalmology case reports · 2024
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

William F FoosOphthalmology, The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA wfoos@mfa.gwu.edu.
Catherine CulpOphthalmology, The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA.
Masumi AsahiOphthalmology, The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA.
Marena PatronasOphthalmology, The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA.
George Washington University · USCarolina Retina Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Siponimod is a sphingosine-1-phosphate receptor modulator used as disease-modifying therapy for relapsing-remitting multiple sclerosis similar to Fingolimod which has been known to cause dose dependent fingolimod associated macular oedema (FAME). We report a case of delayed onset bilateral cystoid macular oedema in a patient with stable proliferative diabetic retinopathy who developed cystoid macular oedema in the setting of siponimod (Mayzent; Novartis Pharmaceuticals; Cambridge, Massachusetts, USA) use. As with FAME, cystoid macular oedema resolved in the patient's eyes with drug cessation and adjunctive topical anti-inflammatory therapy. We highlight unique fluorescein angiographic findings within this class of drugs as well as the clinical challenge posed by comorbid diabetic and inflammatory ophthalmic pathology.

Indexed as

Diabetes MellitusDiabetic RetinopathyMacular EdemaAzetidinesBenzyl CompoundsFingolimod HydrochlorideFluoresceinsHumansVisual AcuityAzetidinesBenzyl CompoundsFingolimod HydrochlorideFluoresceinssiponimodDrugs: CNS (not psychiatric)MaculaMultiple sclerosisRetinaUnwanted effects / adverse reactions

Identifiers

PMID36368737
PMCPMC9660509
OpenAlexW4308916535

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.